Patents Assigned to PHARMA FOODS INTERNATIONAL CO., LTD.
-
Patent number: 11844762Abstract: Problem to be solved: An object of the present invention is to provide a novel fat absorption inhibiting agent. Solution to the problem: The present invention provides a fat absorption inhibiting agent comprising pulverized defatted sesame seeds or a processed product thereof. The present invention also provides a fat absorption inhibiting agent comprising defatted sesame seeds having a 50th percentile particle size of 1 to 200 ?m as determined by laser diffraction/scattering and a compressibility index of 30 to 80%. The fat absorption inhibiting agent of the present invention preferably has lipase inhibitory activity. The present invention also provides a food comprising the agent. The present invention also provides defatted sesame seeds having a 50th percentile particle size of 1 to 200 ?m as determined by laser diffraction/scattering and a compressibility index of 30 to 80%.Type: GrantFiled: February 24, 2021Date of Patent: December 19, 2023Assignees: Pharma Foods International Co .. Ltd., Mitsui DM Sugar Co., Ltd.Inventors: Hiroaki Iitsuka, Sayo Morita, Keita Koga, Atsushi Yamatsu, Mujo Kim, Toma Furuta
-
Publication number: 20230277493Abstract: The present invention relates to a digestive lipase activity inhibitor containing, as an active ingredient, at least one selected from the group consisting of linoleic acid and oleic acid.Type: ApplicationFiled: August 2, 2021Publication date: September 7, 2023Applicants: Pharma Foods International Co., Ltd., Mitsui DM Sugar Co.,Ltd.Inventors: Hiroaki Iitsuka, Sayo Morita, Keita Koga, Atsushi Yamatsu, Mujo Kim, Toma Furuta
-
Patent number: 11447569Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.Type: GrantFiled: March 7, 2016Date of Patent: September 20, 2022Assignees: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Mamoru Sato, Michiyuki Yamada, Satoshi Kanazawa, Masayoshi Toyoura, Yuji Shoya, Kenji Saito, Chihiro Yamazaki
-
Patent number: 11241475Abstract: Provided is an agent for preventing and/or treating osteogenesis imperfecta, osteoporosis and/or osteoarthritis, the agent comprising a peptide consisting of one of the following amino acid sequences: (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (SEQ ID NO: 1) and (b) Val-Asn-Pro-Glu (SEQ ID NO: 2). The agent of the present invention can be orally ingested, has osteogenic function, and has a preventive and/or healing-promoting effect on bone fractures and is therefore very useful for prevention and/or treatment of osteogenesis imperfecta, osteoporosis and/or osteoarthritis.Type: GrantFiled: June 27, 2017Date of Patent: February 8, 2022Assignee: Pharma Foods International Co., Ltd.Inventors: Chihiro Suzuki, Utano Nakamura, Mujo Kim
-
Patent number: 11179424Abstract: An agent of the present invention comprising poultry feet or a processed product thereof, preferably a hydrolysate of an extract of poultry feet, promotes hyaluronic acid production, thereby exhibiting excellent effects of preventing or treating a joint disorder, improving skin dryness, wrinkles or skin tension, moisturizing the skin, etc. The agent is thus useful as a medicament, a quasi-drug, a cosmetic product, a food product or an animal feed.Type: GrantFiled: August 7, 2017Date of Patent: November 23, 2021Assignee: Pharma Foods International Co., Ltd.Inventors: Isafumi Maru, Ji-Yeong An, Sayuri Tanaka, Maya Sakashita, Seiyu Harada, Kazuya Watabe, Masayoshi Aosasa, Mujo Kim, Toshio Nakamura, Utano Nakamura, Hiroaki Iitsuka
-
Patent number: 10806787Abstract: The present invention provides an anti-FSTL1 antibody or a fragment or functional equivalent thereof, wherein the antibody recognizes an epitope in a region selected from the group consisting of amino acid positions 48 to 100, 148 to 162, 193 to 216, 205 to 228, and 272 to 289 of SEQ ID NO: 1 (amino acid sequence of human FSTL1). The present invention also provides a combination product of a FSTL1 suppressor and additional cancer treatment. It is understood that immune defect such as immunosuppression or immunodeficiency is effectively mitigated by the present invention.Type: GrantFiled: February 16, 2016Date of Patent: October 20, 2020Assignee: PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Chie Kudo, Masayoshi Toyoura, Akiko Ishida, Yuji Shoya, Chihiro Yamazaki
-
Publication number: 20200157165Abstract: The present invention provides a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect, in particular, a peptide having osteoblast growth-promoting activity, having 100 amino acid residues or less comprising an amino acid sequence selected from (a) (SEQ?ID?NO:?1) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser- Pro-Tyr-Glu, (b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and (c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b), or a derivative thereof or a salt thereof.Type: ApplicationFiled: December 4, 2019Publication date: May 21, 2020Applicant: PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Chihiro YAMAZAKI, Ji-Yeong AN, Seiyu HARADA, Kazuya WATABE, Mujo KIM
-
Patent number: 10538564Abstract: The present invention provides a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect, in particular, a peptide having osteoblast growth-promoting activity, having 100 amino acid residues or less comprising an amino acid sequence selected from (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu (SEQ ID NO: 1), (b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and (c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b), or a derivative thereof or a salt thereof.Type: GrantFiled: February 25, 2015Date of Patent: January 21, 2020Assignee: PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Chihiro Yamazaki, Ji-Yeong An, Seiyu Harada, Kazuya Watabe, Mujo Kim
-
Patent number: 10154684Abstract: The present invention provides a hair regrowth promoter comprising an egg-yolk protein hydrolysate as an active ingredient. The egg-yolk protein hydrolysate is a safe ingredient produced from a natural source, and therefore can be widely used in daily consumable products, such as food and drink products, medicaments, animal feeds, and dietary supplements, or as a food additive, etc. The promoter etc. of the present invention can be orally administered and is thus very advantageous.Type: GrantFiled: October 30, 2015Date of Patent: December 18, 2018Assignee: PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Seiyu Harada, Toshio Nakamura, Mujo Kim
-
Patent number: 10034911Abstract: The present invention provides a novel active ingredient which can be safely used in preventing, ameliorating or treating diseases related to the cartilage such as cartilage damages and cartilage disorders. Since the egg yolk protein hydrolyzate has an effect on chondrocyte proliferation promotion, it is useful as an active ingredient for preventing, ameliorating or treating cartilage disorders and for preventing, ameliorating or treating joint pain. The egg yolk protein hydrolyzate is a natural-origin material with high safety and, therefore, can be widely used in foods and drinks, medicines, feeds and the like which can be daily ingested.Type: GrantFiled: July 4, 2013Date of Patent: July 31, 2018Assignee: Pharma Foods International Co., Ltd.Inventors: Mujo Kim, Kazuya Watabe, Jiyeong An, Masayoshi Aosasa, Noriko Horie, Kazuyuki Masuda, Katsuhito Asai
-
Publication number: 20180021429Abstract: The present invention provides an anti-FSTL1 antibody or a fragment or functional equivalent thereof, wherein the antibody recognizes an epitope in a region selected from the group consisting of amino acid positions 48 to 100, 148 to 162, 193 to 216, 205 to 228, and 272 to 289 of SEQ ID NO: 1 (amino acid sequence of human FSTL1). The present invention also provides a combination product of a FSTL1 suppressor and additional cancer treatment. It is understood that immune defect such as immunosuppression or immunodeficiency is effectively mitigated by the present invention.Type: ApplicationFiled: February 16, 2016Publication date: January 25, 2018Applicant: PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Chie KUDO, Masayoshi TOYOURA, Akiko ISHIDA, Yuji SHOYA, Chihiro YAMAZAKI
-
Publication number: 20160362466Abstract: The present invention provides a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect, in particular, a peptide having osteoblast growth-promoting activity, having 100 amino acid residues or less comprising an amino acid sequence selected from (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu (SEQ ID NO: 1), (b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and (c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b), or a derivative thereof or a salt thereof.Type: ApplicationFiled: February 25, 2015Publication date: December 15, 2016Applicant: PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Chihiro YAMAZAKI, Ji-Yeong AN, Seiyu HARADA, Kazuya WATABE, Mujo KIM